These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35465769)

  • 1. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.
    Hopson MB; Bhutani D; Sarkaria S; Maurer MS; Griffin JM; Mapara M; Lentzsch S; Chakraborty R
    Leuk Lymphoma; 2022 Sep; 63(9):2109-2113. PubMed ID: 35465769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
    Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
    Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
    Kumar S; Dispenzieri A; Katzmann JA; Larson DR; Colby CL; Lacy MQ; Hayman SR; Buadi FK; Leung N; Zeldenrust SR; Ramirez-Alvarado M; Clark RJ; Kyle RA; Rajkumar SV; Gertz MA
    Blood; 2010 Dec; 116(24):5126-9. PubMed ID: 20798235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
    Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
    [No Abstract]   [Full Text] [Related]  

  • 6. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
    Milani P; Basset M; Nuvolone M; Benigna F; Rodigari L; Lavatelli F; Foli A; Merlini G; Palladini G
    Blood Cancer J; 2020 Sep; 10(8):90. PubMed ID: 32873771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
    Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
    Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
    Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
    Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L; Tian Z; Fang Q
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].
    Miao HL; Shen KN; Su W; Zhang L; Cao XX; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):199-204. PubMed ID: 33910304
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
    Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
    Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
    Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
    Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
    Bomsztyk J; Ravichandran S; Giles HV; Wright N; Berlanga O; Khwaja J; Mahmood S; Wisniowski B; Cohen O; Foard D; Gilbertson J; Rauf MU; Starr N; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore JD; Lachmann H; Harding S; Pratt G; Wechalekar AD
    Blood; 2024 Mar; 143(13):1259-1268. PubMed ID: 38194690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
    Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
    Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
    Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
    Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
    Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
    Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
    Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
    Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
    Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
    Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
    J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
    Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
    Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.